Conestoga Capital Advisors highlighted Bio-Techne Corporation as a performance contributor in its second-quarter 2026 investor letter, citing growing confidence that temporary headwinds are subsiding. The life science research tools and diagnostics company benefited from improving academic funding and continued strength in large pharmaceutical customers, which offset lingering weakness in emerging biotech. During the quarter, Bio-Techne agreed to be acquired by Merck KGaA. As of August 5, 2026, Bio-Techne shares closed at $72.00, giving it a market capitalization of $11.22 billion, with a one-month return of 1.19% and a 52-week gain of 43.57%.
Bio-Techne CorpImproving academic funding and strength in large pharma customers offset biotech weakness, easing headwinds.
Merck KGaAAnnounced acquisition of Bio-Techne, expanding its life science portfolio.
